81. Clinical Geriatrics Case Report Catatonia and neuroleptic malignant syndrome in the NursingHome Cathleen ColónEmeric, MD, and Heidi White, MD. Because http://www.mmhc.com/engine.pl?station=mmhc&template=cgfull.html&id=177

82. AIDS And Neuroleptic Malignant Syndrome colleagues report on what they believe to be the first three reported cases in peoplewith AIDSRelated Dementia of neuroleptic malignant syndrome caused by http://www.aegis.com/news/ads/1988/AD880018.html

Important note: Information in this article was accurate in 1988. The state of the art may have changed since the publication date. "AIDS and Neuroleptic Malignant Syndrome" Lancet (12/24-31/88) Vol. 2, No. 4826/4827, P. 1488 Breitbart, William, et al. Abstract: William Breitbart of Memorial Sloan-Kettering Cancer Center and Cornell Medical College and his colleagues report on what they believe to be the first three reported cases in people with AIDS-Related Dementia of neuroleptic malignant syndrome caused by the dopamine-blocking effects of potent neuroleptic drugs. In all three patients, symptoms of the syndrome appeared following the administration of oral haloperidol. Cessation of the drug and the addition of other drugs resolved the problems. Although researchers have recommended low-dose haloperidol for the management of organic mental disorders in AIDS patients, such patients may have increased susceptibility to the dopamine-blocking effects of potent neuroleptics, Breitbart and colleagues report. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim Elton John AIDS Foundation iMetrikus, Inc.

83. The Serotonin Syndrome The term serotonin syndrome may encourage the presumption that it is an idiosyncraticresponse, as neuroleptic malignant syndrome is usually considered to be http://www.biopsychiatry.com/serotsynd.htm

Serotonin syndrome: history and risk by Gillman PK gillman.k.i@m130.aone.net.au Fundam Clin Pharmacol ABSTRACT T See also: Psychotropical.com (Dr Ken Gillman) MAO SSRIs MAOIs Serotonin ... The Good Drug Guide The Responsible Parent's Guide To Healthy Mood Boosters For All The Family

84. InteliHealth: neuroleptic malignant syndrome. The evidence so far is that atypical antipsychoticdrugs are less likely to cause neuroleptic malignant syndrome. Back to top. http://www.intelihealth.com/IH/ihtIH/WSIHW000/8596/35229/363091.html?d=dmtConten

85. JEFF MANN'S EM GUIDEMAPS - NEUROLEPTIC SYNDROME Appendix. Research criteriae for neuroleptic malignant syndrome (from DSMIV). Alternativecriteriae for the diagnosis of neuroleptic malignant syndrome. http://www.homestead.com/emguidemaps/files/rigidity.htm

EM guidemap - Fever + rigidity + altered LOC Click on any of the headings or subheadings to rapidly navigate to the relevant section of the guidemap Introduction History of the present illness Summary of the clinical features differentiating NMS from SS Diagnostic testing ... Appendix Introduction - this guidemap has been designed to help an ED physician solve the diagnostic dilemma of "fever + rigidity + altered LOC" in an ED patient - this guidemap is mainly focused on helping the physician differentiate between neuroleptic malignant syndrome (NMS) and serotonin syndrome (SS) , with a lesser emphasis on other common causes of "fever + rigidity + altered LOC" History of the present illness - NMS usually develops over 24 - 72 hours , although it may progress more slowly over many days (3 - 10 days) in a patient taking a neuroleptic medication (* SS develops more abruptly within hours of a change in the dose of a provoking drug, or following the addition of an interacting drug eg. IM meperidine administered to a patient taking a MAOI) - NMS typically begins with mental status changes and muscular rigidity => hyperthermia and autonomic dysfunction - the mental status in NMS is always impaired and ranges from agitation => stupor => coma (* SS is usually associated with anxiety, restlessness , agitation or hypomania; and rarely with seizures or stupor/coma - the increased anxiety may be falsely misinterpreted as an exacerbation of the underlying condition requiring treatment with a SSRI)

86. Mioti: Diseases + Conditions Diseases + Conditions neuroleptic malignant syndrome. Search Mioti http://www.mioti.com/cat/condition/condition.asp?Cat=Neuroleptic

87. UCLA Department Of Anesthesiology neuroleptic malignant syndrome; Sudden Infant Death Syndrome; Osteogenesis Imperfecta;Glycogen Storage Disease; Lymphomas; Heat Stroke. To Table of Contents. http://www.anes.ucla.edu/dept/mh.html

MALIGNANT HYPERTHERMIA Malignant hyperthermia (MH) is a pharmacogenetic disease of skeletal muscle. Characteristically patients with this disease have no signs or symptoms except during an anesthetic. When exposed to inhalational anesthetics (those which are gases ), muscle metabolism increases, and a series of signs and symptoms appear, which if left untreated can lead to death. The earliest findings are an increased production of carbon dioxide and signs of increased sympathetic nervous system activity. Malignant Hyperthermia and UCLA The UCLA Department of Anesthesiology maintains one of the few centers in the US and Canada where patients suspected of being MH susceptible can be evaluated and if indicated have a diagnostic biopsy performed. Full time faculty members at UCLA, Dr. Jordan Miller, Dr. Harvey Rosenbaum and Dr. Lorraine Weiss, are three of the 30 national experts who maintain the Malignant Hyperthermia Hotline 24 hours a day, 365 days a year. (Call 1 800 MHHYPER)

88. Public Citizen's ELetter: Adverse Reactions Associated With Olanzapine (ZYPREXA) Reactions Advisory Committee ­. Olanzapine (ZYPREXA) White BloodCell Disorders, Convulsions and neuroleptic malignant syndrome. http://www.citizen.org/ELETTER/ARTICLES/olanzapine.htm

posted May 2000 Report From Australian Adverse Drug Reactions Advisory Committee ­ Olanzapine (ZYPREXA): White Blood Cell Disorders, Convulsions and Neuroleptic Malignant Syndrome This web site is intended only as a reference for use in an ongoing partnership between doctor and patient in the vigilant management of the patient's health. It is not a substitute for a doctor's professional judgement, and serves only as a reminder of concerns that may need discussion. All users are urged to consult with a physician before beginning or discontinuing use of any prescription drug or undertaking any form of self-treatment. This website does not list every possible adverse reaction, interaction, precaution and effect of a drug; and all information is presented without guarantees by the authors and consultants who disclaim all liability in connection with its use. Olanzapine (ZYPREXA) has been approved by the Food and Drug Administration (FDA) for treatment of psychosis. The Australian Adverse Drug Reactions Advisory Committee (ADRAC) reviewed the reports that they had received for the antipsychotic olanzapine (ZYPREXA) in their August 1999 newsletter. Olanzapine was approved in the U.S. in the fall of 1996.

89. NeLMH: Monitoring, Recognising, And Managing Side Effects - Neuroleptic Malignan neuroleptic malignant syndrome (NMS). This syndrome is rare but potentially fatal,and can develop at any time during treatment with antipsychotic medication. http://www.nelmh.org/page_view.asp?c=20&did=2330&fc=005002007

90. Entrez PubMed Olanzapineassociated neuroleptic malignant syndrome. Publication Types Review; Reviewof Reported Cases. MeSH Terms Human; neuroleptic malignant syndrome/blood; http://www.biomedcentral.com/pubmed/12369263

Entrez PubMed Nucleotide Protein ... Books Search PubMed Protein Nucleotide Structure Genome Books CancerChromosomes 3D Domains Domains Gene GEO GEO DataSets HomoloGene Journals MeSH NCBI Web Site OMIM PMC PopSet SNP Taxonomy UniGene UniSTS for Limits Preview/Index History Clipboard ... Text Version Entrez PubMed Overview FAQ Tutorial New/Noteworthy ... E-Utilities PubMed Services Journals Database MeSH Database Single Citation Matcher Batch Citation Matcher ... Cubby Related Resources Order Documents NLM Gateway TOXNET Consumer Health ... PubMed Central Summary Brief Abstract Citation ASN.1 MEDLINE XML UI List LinkOut Related Articles Cited in Books CancerChrom Links Domain Links 3D Domain Links GEO DataSet Links Gene Links Genome Links GEO Links HomoloGene Links Nucleotide Links OMIM Links PMC Links Cited in PMC PopSet Links Protein Links SNP Links Structure Links UniSTS Links Show: Sort Author Journal Pub Date Text File Clipboard E-mail Order Prog Neuropsychopharmacol Biol Psychiatry. 2002 Jun;26(5):897-902. Related Articles, Links Olanzapine-associated neuroleptic malignant syndrome. Kontaxakis VP, Havaki-Kontaxaki BJ, Christodoulou NG, Paplos KG.

91. Karger Publishers CYP2D6 HhaI Genotype and the neuroleptic malignant syndrome Kazuhiko Iwahashi a, Eiji Yoshihara a , Kazuhiko Nakamura b , Kiyoshi Ameno b , Masao Watanabe b http://content.karger.com/ProdukteDB/produkte.asp?Doi=26557

92. Blackwell Synergy - Cookie Absent Risk factors in neuroleptic malignant syndrome. A casecontrol study. 1. CaroffSN. The neuroleptic malignant syndrome. J Clin Psychiatry 1980;4179-83. http://www.blackwell-synergy.com/links/doi/10.1034/j.1600-0447.2003.02385.x/full

Home An Error Occurred Setting Your User Cookie A cookie is a small amount of information that a web site copies onto your hard drive. Synergy uses cookies to improve performance by remembering that you are logged in when you go from page to page. If the cookie cannot be set correctly, then Synergy cannot determine whether you are logged in and a new session will be created for each page you visit. This slows the system down. Therefore, you must accept the Synergy cookie to use the system. What Gets Stored in a Cookie? Synergy only stores a session ID in the cookie, no other information is captured. In general, only the information that you provide, or the choices you make while visiting a web site, can be stored in a cookie. For example, the site cannot determine your email name unless you choose to type it. Allowing a web site to create a cookie does not give that or any other site access to the rest of your computer, and only the site that created the cookie can read it. Please read our for more information about data collected on this site.

93. THE MERCK MANUALSECOND HOME EDITION, What Is Neuroleptic Merck Co., Inc. is a global researchdriven pharmaceutical productscompany. Contact us Worldwide. Home About Merck Products Newsroom http://www.merck.com/mrkshared/mmanual_home2/sb/sb107_3.jsp

94. Catatonic Schizophrenia And The Options For Treatment degree. It has even been suggested that lethal catatonia and neurolepticmalignant syndrome are in fact the same condition (8). http://www.priory.com/psych/cataton.htm

Catatonic Schizophrenia and the Options for Treatment Return to Psychiatry On-Line Contents Daniel J Smith , North Western Mental Health Service, Parkville, Melbourne, Victoria, Australia. *John Summers , Locum Consultant Psychiatrist, Greater Glasgow Primary Care NHS Trust, Larkfield Community Mental Health Team, Garngaber Avenue, Lenzie Glasgow, UK Telephone 0141 776 7100 Fax. 0141 776 7462 *corresponding author Abstract We report a case of catatonic schizophrenia in a young man with particular reference to the options for treatment and the need for effective communication between psychiatrists and neurologists. Careful consideration of the appropriate pharmacotherapy is important because catatonic symptoms can be exacerbated by the use of conventional neuroleptics. Key Points Catatonic symptoms are often overlooked in acute general adult psychiatry wards. Benzodiazepines and ECT are the preferred treatment options for catatonic schizophrenia. Conventional neuroleptics can exacerbate catatonic symptoms to a fatal degree. The role of atypical neuroleptics in catatonic schizophrenia requires further evaluation.

95. Schizophrenia.com - Schizophrenia Medications Information Schizophrenia Information Schizophrenia Medications. SchizophreniaMedications. Table of Contents General Reading/Introductory Reading http://www.schizophrenia.com/ami/meds/bipoltreat.html

document.write(''); Home About Donate/Volunteer Contact ... Schizophrenia Information > Schizophrenia Medications Schizophrenia Medications Table of Contents General Reading/Introductory Reading on Antipsychotic Medications Low Cost Access to Schizophrenia Medications Recommended Books on Schizophrenia-related Psychiatric Medications Side-Effects of Some Schizophrenia Medications ... Sources for Additional Information on Medications The American Psychiatric Association's " Guideline For The Treatment Of Patients With Schizophrenia " states that "Antipsychotic medications are indicated for nearly all acute psychotic episodes in patients with schizophrenia." There is also significant overlap in terms of the medications for schizophrenia and bipolar disorder (Manic Depression). There are two main classifications of medications (from a layman's perspective) the traditional antipsychotic medications (Haldol, etc.), and the newer, "atypical" antipsychotic medications that have come out in the past decade (Clozapine, Geodon, Seroquel, Risperdal, Zyprexa, Abilify, etc.). We recommend you visit our (and other) on-line support groups to learn what people are saying about their success and problems with the different medications. We also recommend you read as much as you can on the medications available, and talk with a psychiatrist, to identify the medications that may be appropriate. Keep in mind that while both the older and newer medications can greatly help a person who has schizophrenia, they all have significant side effects that vary by person and medication, and they are unfortunately not yet a cure for schizophrenia.

96. Guide'EM Clinical Guidelines for Care of the Emergency Patient a project of the Divisionof Emergency Medicine Informatics at the Boston University Department of http://www.ed.bmc.org/EMGuidelines/guideEM.cfm?CCN1_ID=22&CCN2_ID=2&CCN3_ID=6

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

Page 5     81-96 of 96    Back | 1  | 2  | 3  | 4  | 5